New insights in tissue distribution, metabolism, and excretion of [3H]-labeled antibody maytansinoid conjugates in female tumor-bearing nude rats

Drug Metabolism and Disposition

Volumn 44, Issue 7, 2016, Pages 897-910

  Walles, Markus ^a   Rudolph, Bettina ^a   Wolf, Thierry ^a   Bourgailh, Julien ^a   Suetterlin, Martina ^a   Moenius, Thomas ^a   Peraus, Gisela ^a   Heudi, Olivier ^a   Elbast, Walid ^a   Lanshoeft, Christian ^a   Bilic, Sanela ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Translational Clinical Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; DM1 LNL 897 H 3; EMTANSINE; LYSINE 4(MALEIMIDYLMETHYL) CYCLOHEXANE 1 CARBOXYLATE EMTANSINE; P CADHERIN; P CADHERIN RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; ANTIBODY CONJUGATE; CADHERIN; MAYTANSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCASS; CONTROLLED STUDY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; LIVER; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOACTIVITY; RAT; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PROPERTY; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; URINARY EXCRETION; ANIMAL; AREA UNDER THE CURVE; BIOAVAILABILITY; BIOTRANSFORMATION; BLOOD; BREAST TUMOR; CHEMISTRY; HALF LIFE TIME; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; NUDE RAT; PATHOLOGY; TUMOR CELL LINE;

ADMINISTRATION, INTRAVENOUS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; FECES; FEMALE; HALF-LIFE; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; METABOLIC CLEARANCE RATE; RATS, NUDE; TISSUE DISTRIBUTION;

EID: 84975119934     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.069021     Document Type: Article

References (32)

1. Albergaria A, Ribeiro AS, Vieira AF, Sousa B, Nobre AR, Seruca R, Schmitt F, and Paredes J (2011) P-cadherin role in normal breast development and cancer. Int J Dev Biol 55:811-822.
2. Beck A, Terral G, Debaene F, Wagner-Rousset E, Marcoux J, Janin-Bussat MC, Colas O, Dorsselaer AV, and Cianférani S (2016) Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Rev Proteomics 13:157-183.
3. Beck A, Wagner-Rousset E, Ayoub D, Van Dorsselaer A, and Sanglier-Cianférani S (2013) Characterization of therapeutic antibodies and related products. Anal Chem 85:715-736.
4. Davis JA, Rock DA, Wienkers LC, and Pearson JT (2012) In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates. Drug Metab Dispos 40:1927-1934.
5. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, Ouyang Y, Saber H, Lee K, and Koti K, et al. (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18:5845-5849.
6. Deslandes A (2014) Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human phase 1 studies. MAbs 6:859-870.
7. Erickson HK and Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14:799-805.
8. Erickson HK, Widdison WC, Mayo MF, Whiteman K, Audette C, Wilhelm SD, and Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92.
9. Hamuro LL and Kishnani NS (2012) Metabolism of biologics: biotherapeutic proteins. Bioanalysis 4:189-195.
10. Han TH and Zhao B (2014) Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos 42:1914-1920.
11. Hermanson GT (2013) The reactions of bioconjugations, in Bioconjugate Techniques, (Audet J, Preap M, East K, and Halterman K, eds) pp 229-258, Academic Press/Elsevier, London.
12. Kaur S, Xu K, Saad OM, Dere RC, and Carrasco-Triguero M (2013) Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis 5:201-226.
13. Kraynov E, Kamath AV, Walles M, Tarcsa E, Deslandes A, Iyer RA, Datta-Mannan A, Sriraman P, Bairlein M, and Yang JJ, et al. (2016) Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: an industry white paper. Drug Metab Dispos 44:617-623.
14. Lanshoeft C, Stutz G, Elbast W, Wolf T, Walles M, Stoeckli M, Picard F, and Kretz O (2016) Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 30:823-832.
15. Liu Z, Floss HG, Cassady JM, and Chan KK (2005) Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry. J Mass Spectrom 40:389-399.
16. Marcoux J, Champion T, Colas O, Wagner-Rousset E, Corvaïa N, Van Dorsselaer A, Beck A, and Cianférani S (2015) Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate. Protein Sci 24:1210-1223.
17. Menezes D, Abrams TJ, Karim C, Tang Y, Chi Y, Miller K, Fanton C, Ghoddusi M, Wang Z, and Patawaran M, et al. (2015) Abstract 1682: Development and activity of a novel antibody-drug conjugate for the treatment of P-cadherin expressing cancers. Cancer Res 75:1682.
18. Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, Yi JH, Girish S, Dybdal N, and Reynolds T (2013) Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol 273:298-313.
19. Saad OM, Shen BQ, Xu K, Khojasteh SC, Girish S, and Kaur S (2015) Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. Bioanalysis 7:1583-1604.
20. 14C-whole-body autoradiograms. Int J Rad Appl Instrum [A] 38:329-333.
21. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, and Chu YW, et al. (2012a) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910.
22. Shen BQ, Bumbaca D, Yue Q, Saad O, Tibbitts J, Khojasteh SC, and Girish S (2015) Non-clinical disposition and metabolism of DM1, a component of trastuzumab emtansine (T-DM1), in Sprague-Dawley rats. Drug Metab Lett 9:119-131.
23. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons-Reponte KL, Tien J, Yu SF, and Mai E, et al. (2012b) Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30:184-189.
24. Suchocki JA and Sneden AT (1987) Characterization of decomposition products of maytansine. J Pharm Sci 76:738-743.
25. Sun X, Widdison W, Mayo M, Wilhelm S, Leece B, Chari R, Singh R, and Erickson H (2011) Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22:728-735.
26. Thudium K, Bilic S, Leipold D, Mallet W, Kaur S, Meibohm B, Erickson H, Tibbitts J, Zhao H, and Gupta M (2013) American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. MAbs 5:5-12.
27. Tse FLS and Jaffe JM (1991) Use of radioactivity in drug disposition studies, in Preclinical Drug Disposition, Marcel Dekker, New York.
28. van der Heiden PL, Jedema I, Willemze R, and Barge RM (2006) Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol 76:409-413.
29. Wada R, Erickson HK, Lewis Phillips GD, Provenzano CA, Leipold DD, Mai E, Johnson H, and Tibbitts J (2014) Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. Cancer Chemother Pharmacol 74:969-980.
30. Widdison W, Wilhelm S, Veale K, Costoplus J, Jones G, Audette C, Leece B, Bartle L, Kovtun Y, and Chari R (2015) Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies. Mol Pharm 12:1762-1773.
31. Xie H and Blättler WA (2006) In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Expert Opin Biol Ther 6:281-291.
32. Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, Mukhopadhyay P, Gao B, Pacher P, and Wu WJ (2016) Ado-trastuzumab emtansine targets hepatocytes via human epidermal growth factor receptor 2 to induce hepatotoxicity. Mol Cancer Ther 15:480-490.